Considering The EU Launch Of Biosimilar For Remicade, Merck’s 2nd Largest Drug, Does The Company Face Meaningful EPS Decline In 2016?
Merck’s EPS Impact Due To Remicade Biosimilar Competition In 2016 Is Insignificant, < 2%
Have more questions about Merck? See the links below.
- What’s Merck’s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas?
- What Led To Nearly 15% Decline In Merck’s Revenues & EBITDA In The Last 5 Years?
- How Has Merck’s Revenue Composition Changed In The Last 5 Years?
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- At $100 Does Merck Stock Have Room For Growth?
- Should You Pick Merck Stock Over Coca-Cola?
- Should You Buy Merck Stock After An Upbeat Q2?
- How Has Merck Stock Performed During The 2022-23 Inflation Shock?
- Is Merck Stock A Better Pick Over ABBV?
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)